SalioGen Therapeutics stock

SalioGen Therapeutics Stock

HealthTech

Looking to sell SalioGen Therapeutics stock or options?

Contact us
Founded: 2020Funding to Date: $156M
Visit website

SalioGen Therapeutics operates a genome engineering platform designed to offer safe, affordable, and long-lasting non-viral gene therapies to patients suffering from inherited diseases. The company's gene engineering technology, derived from mammals, can be utilized in potentially curative non-viral gene therapy. This allows the healthcare industry to enhance cell therapy, cell engineering, and biologics production for patients in need.

Investors Include:

GordonMD Global Investments, Partners Investment, Cystic Fibrosis Foundation, D1 Capital Partners, General Inception, Fidelity Management & Research, Retinal Degeneration Fund, EPIQ Capital Group, PBM Capital, SymBiosis Capital Management, T. Rowe Price Group.